Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People with a confirmed diagnosis of an advanced or spreading solid tumour who have already tried standard cancer treatments that did not work, or who could not tolerate those treatments (dose escalation part of the trial).
• People with a confirmed diagnosis of advanced or spreading ovarian cancer, cervical cancer, pancreatic cancer, or colorectal cancer who have already tried certain prior cancer treatments (dose expansion part of the trial).
• People aged 18 or older at the time of signing the consent form.
• People who have at least one measurable area of cancer that can be tracked on scans, as defined by standard measurement guidelines (dose expansion part only).
• People whose general health and ability to carry out daily activities is rated as 0 or 1 on a standard medical scale; a rating of 2 may be considered if it is caused by the cancer progressing (confirm with trial site).
• People whose heart, liver, kidneys, and other organs are functioning well enough, based on blood tests taken within 7 days before starting the study drug.
• People with a life expectancy of at least 12 weeks.
• Women who could become pregnant must have a negative pregnancy test within 7 days before the first dose.
• People who are not permanently unable to have children must be willing to use highly effective contraception throughout the study and for 6 months after the last dose.
• People who are able to give written consent and are willing to follow the study requirements.

Who may not be able to join:

• People who have had a severe reaction to other monoclonal antibodies or antibody-drug treatments in the past, or who are known to be allergic to any ingredient in the study drug XNW28012.
• People who have received any anti-cancer treatment — including chemotherapy, immunotherapy, targeted drugs, or experimental treatments — within 28 days before the first dose.
• People who have another active cancer, other than the specific cancer types being studied or a localised cancer that has already been fully treated.
• People who have received a live vaccine within 4 weeks before the first dose (standard inactivated flu vaccines are generally allowed; confirm with trial site).
• People who have received certain white blood cell-boosting injections (G-CSF) within 1–2 weeks before screening, depending on the type used.
• People who still have significant side effects from previous cancer treatments that have not improved to a mild level or stabilised (hair loss is generally an exception).
• People with a recent history of certain brain blood vessel problems or stroke within the past 3 months, unless the condition is stable (confirm with trial site).
• People who have certain high-risk blood count results (confirm with trial site for specific values).
• People who are unwilling or unable to provide a tumour tissue sample for a required protein expression test.
• People with significant heart or brain blood vessel conditions.
• People with an active eye surface disease at the time of screening, or who have ever had a scarring condition of the eye called cicatricial conjunctivitis.
• People who have ever had a severe skin reaction known as Toxic Epidermal Necrolysis (TEN) or Stevens-Johnson Syndrome.
• People who have had major surgery within 28 days before the first dose, unless it was a minor procedure such as insertion of a small medical line.

Important: Always verify eligibility with the trial site directly before applying.